Bull and Bear

Bull and Bear

At $58.30 Maximus trades at roughly 6.9 times forward adjusted earnings and a 15.5% forward free-cash-flow yield after a 41% fall, even as management raised fiscal-2026 guidance twice on the way down [1]. The buy case is a cheap, cash-generative incumbent in mandatory government programs; the bear case is that the same revenue and record margins concentrate in one veterans-exam contract up for recompete on December 31, 2026, with reported cash flattered by a receivables facility. This chapter reconciles the two rather than declaring a winner.

What the company is

Maximus administers the back office of U.S. government benefit programs — Medicare and Marketplace help lines, Medicaid eligibility, welfare-to-work, student-loan servicing, and clinical exams for veterans — under multi-year contracts, with about 11% of revenue overseas (Government's Back Office). Roughly 88% of the $5.4 billion revenue base is government, about 60% sits in the ten largest contracts, and one federal agency supplies close to a fifth. The model is capital-light (capex 1–2% of revenue) and turns earnings into cash at about 1.3 times net income over a cycle (Cash Conversion). Backlog was $15.3 billion at September 30, 2025, about 2.8 times revenue [2].

What went wrong

The stock fell about 41%, from $98.93 on January 22, 2026 to $58.30 on July 17, 2026, without a matching fall in cash generation. Most of the move is sector-wide. The Department of Government Efficiency and a six-week federal government shutdown repriced the entire government-services group in 2025, and the damage at peers was real: ICF disclosed that revenue from federal clients fell 25% year on year in 2025 on contracts canceled between February and May plus the shutdown [3], and SAIC's full-year revenue declined about 3% organically with fiscal-2027 guided to further contraction it attributed mainly to recompete losses [4].

Maximus's own exposure to the efficiency drive has been slight — management sized the direct impact at about $4 million, "a de minimis figure on our base of $5 billion plus of revenue" [5]. What repriced its multiple were three company-specific worries: fiscal-2026 revenue guided flat-to-down ($5.2–5.35 billion against $5.43 billion), the December 31, 2026 recompete of the veterans-exam contract that anchors both revenue and margin, and a days-sales-outstanding spike at one federal customer that pushed first-half free cash flow negative. Over the same months, management raised fiscal-2026 adjusted-EPS guidance twice, to $8.25–8.55, and lifted the adjusted EBITDA margin guide to 14.2% [6]. The de-rating outran the change in the numbers, which is the setup the valuation chapter priced (The De-Rating).

Source: derived from FY2025 free cash flow of $366.2M [7], FY2026 guidance of $450–500M FCF and $739–761M adjusted EBITDA [8], and market data as of 2026-07-17 (52.5M shares, ~$3.06B market cap, ~$1.38B net debt).

The buy case

Three things carry the bull argument, each cashed to a number.

First, the price capitalizes cash cheaply and the cash is real over a cycle. Trailing free cash flow of $366 million on a roughly $3.06 billion market cap is a 12% yield; the $450–500 million fiscal-2026 guide is 15.5% [9]. Over fiscal 2020–2025 operating cash flow ran about 1.5 times net income and the accrual test was benign (Cash Conversion).

Second, the franchise has defended itself. Management models a rebid win rate of "ninety percent, plus or minus three" that it says has held for five years, on mandatory, bipartisan programs that persist across administrations [10]. The efficiency drive that cut peers barely touched Maximus, and H.R.1's Medicaid work requirements and semi-annual redeterminations, effective December 31, 2026, are a fiscal-2027 volume tailwind that states will need third parties to administer (Recompete Durability).

Third, earnings are growing on flat revenue and the driver looks structural. U.S. Federal Services operating margin rose to 17.6% in the second quarter of fiscal 2026 from 15.3%, on just 1.5% ex-disaster organic growth, which management attributes to technology that "decouple[s] labor costs from our ability to process more volumes" — a concrete example being AI that organizes 5,500-page veterans' medical files [11], [12]. Management banked the durable half twice, raising the near-term adjusted EBITDA target range and the Federal margin guide (Operating Leverage). Discounted at 10%, Maximus's $58.30 price implies free cash flow declining about 5% a year in perpetuity, yet its direct 2025 federal-efficiency hit was about $4 million (0.07% of revenue) and it raised earnings guidance twice while peers ICF and SAIC absorbed 25% and roughly 3% revenue declines, while free cash flow merely holding flat would support about $90 a share [13].

Source: Gordon-growth reverse-DCF derived from the $475M FY2026 FCF midpoint (~$9.04/share on 52.5M shares) at a 10% discount rate; normalized base uses ~$400M mid-cycle FCF [14], [15]. Current price $58.30 as of 2026-07-17.

The bear case

The counter-argument does not need a collapse; it needs erosion, and it has four supports.

The recompete is concentrated, not diversified. The 90% win rate is a portfolio average; the veterans-exam work runs through December 31, 2026 for all vendors, the VA had not published a rebid timeline as of the May 2026 call, and management itself calls it "the largest" recompete [16]. Because that same clinical work drives the record Federal margin, a single adverse award hits both revenue and earnings (Operating Leverage).

The reported cash leans on a facility and on timing. Excluding the receivables-purchase facility — whose ceiling was raised from $250 million to $350 million — days sales outstanding at March 31, 2026 were 102 rather than the reported 78, and first-half operating cash flow was negative $54.9 million against a $450–500 million full-year free-cash-flow guide [17]. The year therefore depends on a September collection catch-up of the kind that produced $642 million of free cash flow in the fourth quarter of fiscal 2025 alone [18].

Part of the trailing base is a fading peak. Fiscal 2024–25 profit rode roughly 3 points of non-recurring volume (disaster support, a backlog-reduction push, the PACT Act ramp) that management is removing from the fiscal-2026 guide, and record Federal margins sit well above the 10–12% the segment targeted two years earlier [19]. On a normalized ~$400 million free-cash-flow base, the whole scenario ladder shifts down about 15%, and the priced-in decline is only about 3% a year — a lower bar for the bear to clear (The De-Rating).

And management paid up for its own stock. Maximus repurchased about 7.8 million shares for roughly $608 million since October 2024 at a blended ~$78, with the heaviest fiscal-2025 buying at $87.64; that block is worth about $455 million at $58.30 (Capital Allocation). The share reduction is permanent, but part of the drawdown is capital the company itself deployed above the current price.

The reconciliation

The bull and bear arguments do not dispute the facts; they read the same facts differently and are decided by different, checkable outcomes.

Sources: FY2026 guidance and buybacks [20]; win rate [21]; recompete [22]; margin and DSO [23], [24].

On the evidence, the drawdown looks predominantly like a terminal-value de-rating rather than a markdown of current cash generation: the company raised guidance twice as the stock halved, and even a normalized cash base leaves the price implying a slow perpetual decline. The strongest fact against that read is concentration — revenue and record margin sit in the same veterans-exam contract facing recompete, so one adverse 2026 award would validate more of the bear case than any macro fear. What would move the read is not sentiment but two dated events: the VA rebid outcome and whether the September collection catch-up arrives.

What to watch

Each item below is falsifiable, tied to a filing line, and carries a threshold that would change the read.

Sources: recompete and DSO targets [25], [26]; H.R.1 timing and buyback authorization [27].

A note on tradability

The equity clears a value investor's size test: average daily dollar volume runs near $47 million with annual turnover above 250%, so a position can be built and exited without moving the stock (The De-Rating). Realized volatility of roughly 33% (around its 80th percentile) is a reasonable proxy for how the market prices the recompete overhang. Live long-dated option liquidity and implied volatility — open interest and pricing on at-the-money contracts more than a year out — sit outside this corpus and could not be sourced from market data during this work; a reader who needs the options leg for position construction should pull it from a live options feed rather than infer it from the equity.

The report's central question resolves into these watch items. The price already pays for erosion; the evidence for durability is real but concentrated in one contract whose recompete lands within eighteen months.